CYP3A5*3C (AGT haplotype) was associated to lower basal CYP3A5 mRNA expression in HC (p<0.045), however none of the haplotype groups impacted treatment.
This study examined the associations between the CYP3A4*1G, CYP3A4*22, CYP3A5*3 and PPARA rs4823613 A>G polymorphisms and the phenotypes of CYP3A estimated by the ratio of 6β-hydroxycortisol:cortisol in urine, and the low-density lipoprotein cholesterol response to simvastatin in Chinese patients with hypercholesterolemia.
We investigated the effect of four polymorphisms in CYP3A4, CYP3A5 and ABCB1 genes on response to atorvastatin and CYP3A4 activity in Chilean subjects with HC.
In order to evaluate the influence of CYP3A5 variants on response to lowering-cholesterol drugs, 139 individuals with hypercholesterolemia were selected.